OncoMatch/Clinical Trials/NCT06353126
DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
Is NCT06353126 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies non-drug interventions for liver cancer.
The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to living donor liver transplantation can prolong the recurrence-free survival in patients with hepatocellular carcinoma (HCC). It is a single-center, exploratory study. The patients scheduled for living donor liver transplantation receive DEB-TACE 2 weeks prior to the surgery. The primary outcome: Recurrence-free survival (RFS) The secondary outcome:1) Overall survival (OS)；2) Pathological response rate (Pathological Response); 3) Proportion of patients completing living donor liver transplantation; 4) Adverse events related to DEB-TACE.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
White blood cell count <3.0x10^9/L, platelet count <50x10^6/L, and unable to correct [excluded]
Kidney function
creatinine >176.8 umol/L or creatinine clearance rate <30ml/min [excluded]
Liver function
Child-Pugh score A-B grade; no severe hepatic encephalopathy; no irreversible hepatic artery to hepatic vein shunt
Cardiac function
Coexisting pulmonary arterial hypertension (moderate to high risk, WHO Grade III-IV) [excluded]; cardiopulmonary insufficiency [excluded]
Child-Pugh score A-B grade; Severe hepatic encephalopathy [excluded]; Renal dysfunction, creatinine >176.8 umol/L or creatinine clearance rate <30ml/min [excluded]; White blood cell count <3.0x10^9/L, platelet count <50x10^6/L, and unable to correct [excluded]; Coexisting pulmonary arterial hypertension (moderate to high risk, WHO Grade III-IV) [excluded]; cardiopulmonary insufficiency [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify